A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
← catalyst calendarSponsored by Almirall, S.A. (industry) · ALM.MC — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
42actual
Sites
7
Country
Czechia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-04 | actual | When the study began enrolling |
| Primary completion | Jan 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Intervention
- Drug: Tildrakizumab — also filed as IL-23p19 inhibitor
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in 5-item World Health Organization Wellbeing Index (WHO-5) Score
measured Baseline to Week 28
Permalink · ALM.MC's whole pipeline · Catalyst calendar · Every registered study · What changed